
Annual report 2024
added 12-06-2025
Novartis AG Net Debt 2011-2025 | NVS
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Novartis AG
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| - | 16.9 B | 9.49 B | 18.8 B | 19.6 B | 16.7 B | 17.2 B | 7.34 B | 11.3 B | 14.2 B | 16.5 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 19.6 B | 7.34 B | 14.8 B |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Biotechnology industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Arbutus Biopharma Corporation
ABUS
|
-107 M | $ 4.79 | 2.35 % | $ 795 M | ||
|
MorphoSys AG
MOR
|
163 M | - | 2.43 % | $ 254 M | ||
|
Aeglea BioTherapeutics
AGLE
|
-30.2 M | - | - | $ 1.01 B | ||
|
Aclaris Therapeutics
ACRS
|
-22 M | $ 3.04 | 4.83 % | $ 235 M | ||
|
Alpine Immune Sciences
ALPN
|
-63.9 M | - | - | $ 2.17 B | ||
|
AlloVir
ALVR
|
-62.7 M | - | 4.14 % | $ 49.1 M | ||
|
Ampio Pharmaceuticals
AMPE
|
-12 M | - | -11.43 % | $ 502 K | ||
|
Applied Molecular Transport
AMTI
|
-56.5 M | - | - | $ 10.1 M | ||
|
Aptevo Therapeutics
APVO
|
-3.28 M | $ 0.93 | -8.81 % | $ 257 K | ||
|
Athersys
ATHX
|
-27.6 M | - | 3.77 % | $ 22.4 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
-402 M | - | - | $ 40.3 B | ||
|
Avenue Therapeutics
ATXI
|
-3.13 K | - | -52.27 % | $ 4.45 M | ||
|
AVROBIO
AVRO
|
-76.6 M | - | 1083.1 % | $ 745 M | ||
|
BioDelivery Sciences International
BDSI
|
-33.1 M | - | -4.8 % | $ 255 M | ||
|
Ascendis Pharma A/S
ASND
|
-195 M | $ 212.81 | 1.71 % | $ 5 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
-824 K | - | -1.52 % | $ 24.7 M | ||
|
BeiGene, Ltd.
BGNE
|
-2.44 B | - | 0.49 % | $ 251 B | ||
|
Midatech Pharma plc
MTP
|
-6.17 M | - | -18.52 % | $ 27.3 M | ||
|
BioVie
BIVI
|
-17.2 M | $ 1.27 | -3.05 % | $ 1.88 M | ||
|
Alterity Therapeutics Limited
ATHE
|
-34.7 M | $ 3.1 | 0.16 % | $ 7.46 B | ||
|
Bellicum Pharmaceuticals
BLCM
|
-34.7 M | - | -9.72 % | $ 5.89 M | ||
|
Berkeley Lights
BLI
|
-60.5 M | - | -7.31 % | $ 87 M | ||
|
bluebird bio
BLUE
|
-163 M | - | - | $ 546 M | ||
|
Calithera Biosciences
CALA
|
-56.5 M | - | -10.95 % | $ 876 K | ||
|
Catalyst Biosciences
CBIO
|
-33.1 M | $ 12.37 | 2.06 % | $ 814 M | ||
|
Cerevel Therapeutics Holdings
CERE
|
-33.6 M | - | - | $ 7.29 B | ||
|
Biophytis SA
BPTS
|
-4.01 M | - | -13.47 % | $ 169 M | ||
|
Институт стволовых клеток человека
ISKJ
|
246 M | - | - | - | ||
|
ARCA biopharma
ABIO
|
-60.6 M | - | 1052.0 % | $ 415 M | ||
|
Celldex Therapeutics
CLDX
|
-24.5 M | $ 26.83 | 0.94 % | $ 1.73 M | ||
|
Acasti Pharma
ACST
|
-27.4 M | - | 4.01 % | $ 150 M | ||
|
Adaptimmune Therapeutics plc
ADAP
|
-119 M | - | -15.15 % | $ 60.3 M | ||
|
Celsion Corporation
CLSN
|
-4.73 M | - | -6.63 % | $ 13.9 M | ||
|
BioNTech SE
BNTX
|
-973 M | $ 95.03 | 0.95 % | $ 27.2 B | ||
|
Albireo Pharma
ALBO
|
-239 M | - | -0.23 % | $ 916 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
469 M | $ 26.81 | 1.36 % | $ 1.3 B | ||
|
Corcept Therapeutics Incorporated
CORT
|
-121 M | $ 83.59 | 1.95 % | $ 8.63 B | ||
|
Anika Therapeutics
ANIK
|
-46 M | $ 9.48 | 0.96 % | $ 139 M | ||
|
CorMedix
CRMD
|
-43 M | $ 12.19 | 1.75 % | $ 621 M | ||
|
Cortexyme
CRTX
|
-68.6 M | - | -1.05 % | $ 67.1 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
-3.5 M | $ 0.18 | -25.03 % | $ 392 M | ||
|
CTI BioPharma Corp.
CTIC
|
18.3 M | - | - | $ 1.2 B | ||
|
Arena Pharmaceuticals
ARNA
|
-25.4 M | - | -6.81 % | $ 3.04 B | ||
|
Acer Therapeutics
ACER
|
-2.08 M | - | 2.71 % | $ 14 M | ||
|
Axon Enterprise
AXON
|
-404 M | $ 591.15 | 0.02 % | $ 44.8 B | ||
|
Ayala Pharmaceuticals
AYLA
|
-657 K | - | - | $ 7.46 M | ||
|
Aytu BioScience
AYTU
|
-19.9 M | $ 2.53 | -0.39 % | $ 15.9 M | ||
|
AstraZeneca PLC
AZN
|
9.86 B | $ 92.45 | 0.34 % | $ 96.9 B | ||
|
Acorda Therapeutics
ACOR
|
114 M | - | -24.86 % | $ 820 K | ||
|
Brickell Biotech
BBI
|
-29.7 M | - | -5.38 % | $ 6.06 M |